Overview
To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia.
Description
To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia.
Subjects' improvement in disease symptoms and overall Quality of life will be assessed.
Eligibility
Inclusion Criteria (IC):
- IC1. Meets criteria established in the locally applicable Vercise System Directions for Use (DFU) for dystonia.
- IC2. At least 7 years old. Parent or guardian consent is required in patients who are younger than 18 years at the time of consent.
Exclusion Criteria (EC):
- EC1. Meets any contraindication in the Vercise System locally applicable Directions for Use.